NEED FOR DRUG PRICE CONTROL IN INDIA
Journal Title: International Journal of Drug Regulatory Affairs - Year 2013, Vol 1, Issue 4
Abstract
India is one of the developing countries. A substantial proportion of population of this country is largely exposed to the drug market whose purchasing power is extremely low. Around 42% population of this country lives under the National poverty line ($1.25 per day). Vital issue concerning them is to access the health care facility at an affordable cost. Medicine is a part of health care cost and it costs to around 70% to 80% of total cost. Thus, cost of medicine is a governing factor of health care system especially when it comes to price control of health care facilities. To bring down the cost of health care facilities, government spends money for health care facilities. A comparative expenditure made by state government is depicted in this article. NPPA (National Pharmaceutical Pricing Authority) is the Indian pharmaceutical pricing regulating authority and it achieves its objectives by implementing the DPCO (Drug Pricing control order). In spite of existence of the DPCO, drastic price variation is observed between the products of same API (Active Pharmaceutical Ingredient) and several factors are responsible for the same. To overcome the stated problem and monopolistic trade practice by patent holder/brand manufacturer, TRIPS (Trade Related Intellectual Properties Rights) provides Compulsory Licenses which has its unique role to play in affordability of medicines. Essential medicine is a basic requirement of health care system to serve their customers and hence an effective and overt price control on drugs is the need of present. This study will thus try to justify the need to bring NLEM (National List of Essential Medicine) under DPCO.
Authors and Affiliations
Parasiya Sachin K. R, Balamuralidhara V, Kumar Pramod T. M, Dave A. J. , Gujarati R R, Shukla A
Keywords
Related Articles
- EP ID EP338259
- DOI -
- Views 112
- Downloads 0
QbD APPROACH FOR STABILITY INDICATING HPLC METHOD FOR DETERMINATION OF ARTEMETHER AND LUMEFANTRINE IN COMBINED DOSAGE FORM
The present paper reports a highly selective, sensitive and robust stability indicating RP-HPLC method using QbD approach, developed and validated for determination of Artemether and Lumefantrine in combined dosage form....
REVIEW ON OCULAR DRUG DELIVERY SYSTEM AND ITS DEVICES
Ocular drug delivery system for the treatment of eye diseases has become popular and feasible in the past few years. Improving ocular contact time, enhancing corneal permeability and site specificity are the key points f...
RISK DRIVERS OF FALSIFIED AND SUB-STANDARD MEDICINES IN EAST AFRICA: PERCEPTIONS AND PRACTICES OF PHARMACEUTICAL DRUG FACILITY OWNERS/EMPLOYEES
An interview survey was conducted among drug shop owners to investigate the access to and perception of counterfeit medication along transport corridors of East Africa spanning Kenya, Tanzania, Uganda and Democratic Repu...
MARKETING AUTHORIZATION OF GENERIC DRUG: GLOBAL ISSUE AND CHALLENGES
Generic medicines are those whose patent protection has expired, and which may be produced by manufacturers other than the innovator company. Use of generic medicines has been increasing in recent years, primarily as a c...
STEPS FOR SUCCESS IN SOURCING OF HARD GELATIN CAPSULES FOR PHARMACEUTICAL USE
The sourcing of raw Gelatin for manufacturing hard Gelatin Capsules is a very critical function. It involves a thorough quality audit of the suppliers. The most critical audit points are: source of Gelatin used, quality...